Mural Oncology Q3 2024 GAAP EPS $(1.87) Beats $(1.98) Estimate, Cash, Cash Equivalents, And Marketable Securities Of $175.5M Are Expected To Fund Its Operations Into The Fourth Quarter Of 2025
Mural Oncology Q3 2024 GAAP EPS $(1.87) Beats $(1.98) Estimate, Cash, Cash Equivalents, And Marketable Securities Of $175.5M Are Expected To Fund Its Operations Into The Fourth Quarter Of 2025
Mural Oncology 2024年第三季度的GAAP每股收益爲$(1.87)，超過$(1.98)的預估，預計現金、現金等價物和可交易證券總額爲$17550萬，將用於支持其業務運作直至2025年第四季度。
Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(1.87) per share which beat the analyst consensus estimate of $(1.98) by 5.56 percent. This is a 39.09 percent increase over losses of $(3.07) per share from the same period last year.
Mural Oncology（納斯達克：MURA）報告每股虧損$(1.87)，超過分析師預期的$(1.98)約5.56％。這比去年同期每股虧損$(3.07)增加了39.09％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間